Molecular techniques in the diagnosis of deep and systemic mycosis.
Making an early and sensitive diagnosis of invasive fungal infections in high-risk patients is mandatory, because it has major consequences on the effectiveness of antifungal therapy. Molecular assays have the potential to become the cornerstone of diagnosis, allowing for rapid, reliable detection of minute amounts of fungal DNA in various specimens at a low cost. PCR is gaining popularity as the platforms become more automated and commercially available; however, further studies are needed to explore the diagnostic value in patient subgroups (ie, children) and to define whether the underlying disease or the use of antifungal prophylaxis may influence assay results. Individualized management of high-risk patients would be desirable to integrate preemptive therapy strategies, and individual host and genetic factors. Pharmacological and epidemiological considerations should also be evaluated.
Universitätsklinikum Würzburg, Medizinische Klinik II, Josef Schneider Str. 2, Würzburg 97080, Germany.
Jan
J
Springer
Hermann
H
Einsele
Juergen
J
Loeffler
D000935:Antifungal Agents / Q000627:therapeutic use; D000946:Antigens, Fungal / Q000032:analysis / Q000276:immunology; D004271:DNA, Fungal / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D025202:Molecular Diagnostic Techniques; D009181:Mycoses / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016133:Polymerase Chain Reaction / Q000379:methods; D012307:Risk Factors
D000935:Antifungal Agents; D000946:Antigens, Fungal; D004271:DNA, Fungal